About Albert David Ltd
Data last updated:
Albert David Ltd is a public limited company based in Kolkata, West Bengal, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 16 November 1938 and has been in existence for over 88 years.
The company is registered with the Registrar of Companies (ROC), Kolkata, under CIN L51109WB1938PLC009490. Its GSTIN is 19AACCA3933D1ZZ (West Bengal). The company holds 21 GST registrations, of which 8 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 524075 and NSE: ALBERTDAVD.
The company has an authorised share capital of ₹10 Cr and a paid-up capital of ₹5.71 Cr. It is led by directors including Arun Kumar Kothari (Whole-Time Director) and Prabhawati Devi Kothari.
Its last annual general meeting (AGM) was held on 02 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 'D' Block 3rd Floor Gillander House Netaji Subhas Road, Kolkata, West Bengal, India – 700001.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹333.6 Cr, a decline of 3.5% compared to the previous year. For the same year it recorded a net loss of ₹1.72 Cr (net margin -0.5%) and EBITDA of ₹5.73 Cr (EBITDA margin 1.7%). The net worth stands at ₹391.54 Cr (down 0.2% YoY). Total assets are valued at ₹427.86 Cr (up 3.9% YoY).
The company has about 1,344 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Albert David India. As per MCA filings, the company has open charges of ₹56 Cr and satisfied charges of ₹43 Cr on record. Court records list 177 cases involving the company, including 73 filed by the company and 104 filed against it; 36 cases are pending. The company has 34 deals on record (33 market trades, 1 acquisition); the latest was in August 2024. Its 9 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Halewood Laboratories Private Limited with revenue of ₹430.29 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website albertdavidindia.com.
Company details
CIN history
Albert David has one previous CIN (Corporate Identification Number): U51109WB1938PLC009490. The current CIN is L51109WB1938PLC009490, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L51109WB1938PLC009490 | Current |
| U51109WB1938PLC009490 | Previous |
Contact details
Albert David Ltd's registered office is in Kolkata, West Bengal. Its website is albertdavidindia.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address'D' Block 3rd Floor Gillander House Netaji Subhas Road, Kolkata, West Bengal, India – 700001
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Albert David Ltd, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Albert David operates one associated brand: Albert David India. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical formulations, infusions, and syringes are manufactured. | albertdavidindia.com |
Business activity
The main business activities of Albert David are manufacturing and trade. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and wholesale trading. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Albert David Ltd, buy the company report.
Financials of Albert David Ltd
FY 2025-26 filings availableAlbert David Ltd reported revenue of ₹333.6 Cr (down 3.5% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 334 | 346 | 362 | 342 | 314 | 247 | 321 |
| Revenue growth | -3.5% | -4.6% | +6.1% | +9.0% | +26.7% | -22.9% | - |
| EBITDA | 5.73 | 3.17 | 46.98 | 44.46 | 40.93 | 19.28 | 30.52 |
| EBITDA margin | +1.7% | +0.9% | +13.0% | +13.0% | +13.1% | +7.8% | +9.5% |
| Profit before tax | 0.52 | 25.23 | 97.27 | 50.73 | 47.29 | 27.45 | 28.98 |
| Net profit | (1.72) | 16.86 | 75.40 | 36.16 | 32.88 | 21.40 | 18.97 |
| Net profit margin | -0.5% | +4.9% | +20.8% | +10.6% | +10.5% | +8.7% | +5.9% |
| EPS (₹) | (2.62) | 30.14 | 132.15 | 63.38 | 61.78 | 38.80 | 33.59 |
| Balance sheet | |||||||
| Total assets | 428 | 412 | 398 | 329 | 298 | 261 | 240 |
| Net worth | 392 | 392 | 383 | 312 | 279 | 244 | 223 |
| Total debt | 29.58 | 12.32 | 3.32 | 5.32 | 5.67 | 1.62 | 2.04 |
| Cash & bank | 32.77 | 1.69 | 31.16 | 25.22 | 18.56 | 35.37 | 6.75 |
| Net working capital | 63.15 | 18.63 | 21.01 | 43.22 | (7.09) | 29.79 | 22.91 |
| Cash flow | |||||||
| Cash from operations | (7.66) | (28.44) | 45.50 | 10.52 | 40.36 | 36.61 | 30.25 |
| Cash from investing | (4.38) | 23.30 | (33.24) | (4.98) | (39.62) | (36.68) | (19.92) |
| Cash from financing | 11.92 | 0.11 | (8.27) | (6.36) | (4.88) | (1.71) | (10.33) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 101 | 85.86 | 89.93 | 87.24 | 70.57 | 74.89 | 83.08 | 98.44 |
| Revenue growth (YoY) | +43.6% | +14.7% | +8.3% | -11.4% | -21.0% | - | - | - |
| Other income | 27.96 | (24.84) | 12.40 | (2.14) | 22.04 | (5.11) | (9.01) | 20.64 |
| Total expenses | 90.70 | 83.11 | 79.10 | 84.70 | 81.22 | 79.64 | 82.41 | 92.21 |
| EBITDA | 10.64 | 2.75 | 10.83 | 2.54 | (10.65) | (4.75) | 0.67 | 6.23 |
| EBITDA margin | +10.5% | +3.2% | +12.0% | +2.9% | -15.1% | -6.3% | +0.8% | +6.3% |
| Depreciation | 2.29 | 2.72 | 2.42 | 2.23 | 2.39 | 1.82 | 1.70 | 1.67 |
| Interest | 0.52 | 0.43 | 0.90 | 0.75 | 0.55 | 0.13 | 0.13 | 0.06 |
| Profit before tax | 35.79 | (25.24) | 19.91 | (2.58) | 8.45 | (11.81) | (10.17) | 25.14 |
| Tax | 3.80 | (3.80) | 4.60 | 0.72 | 0.50 | (1.48) | (0.78) | 7.06 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 101 | 85.86 | 89.93 | 87.24 | 70.57 | 74.89 | 83.08 | 98.44 |
| Revenue growth (YoY) | +43.6% | +14.7% | +8.3% | -11.4% | -21.0% | - | - | - |
| Other income | 27.96 | (24.84) | 12.40 | (2.14) | 22.04 | (5.11) | (9.01) | 20.64 |
| Total expenses | 90.70 | 83.11 | 79.10 | 84.70 | 81.22 | 79.64 | 82.41 | 92.21 |
| EBITDA | 10.64 | 2.75 | 10.83 | 2.54 | (10.65) | (4.75) | 0.67 | 6.23 |
| EBITDA margin | +10.5% | +3.2% | +12.0% | +2.9% | -15.1% | -6.3% | +0.8% | +6.3% |
| Depreciation | 2.29 | 2.72 | 2.42 | 2.23 | 2.39 | 1.82 | 1.70 | 1.67 |
| Interest | 0.52 | 0.43 | 0.90 | 0.75 | 0.55 | 0.13 | 0.13 | 0.06 |
| Profit before tax | 35.79 | (25.24) | 19.91 | (2.58) | 8.45 | (11.81) | (10.17) | 25.14 |
| Tax | 3.80 | (3.80) | 4.60 | 0.72 | 0.50 | (1.48) | (0.78) | 7.06 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 334 | 346 | 362 | 342 | 314 | 247 | 321 |
| Revenue growth | -3.5% | -4.6% | +6.1% | +9.0% | +26.7% | -22.9% | - |
| Other income | 7.45 | 29.58 | 57.55 | 15.40 | 15.84 | 17.18 | 7.11 |
| Total expenses | 328 | 343 | 315 | 297 | 273 | 228 | 290 |
| Employee cost | 102 | 109 | 88.43 | 81.07 | 85.38 | 82.70 | 90.34 |
| EBITDA | 5.73 | 3.17 | 46.98 | 44.46 | 40.93 | 19.28 | 30.52 |
| EBITDA margin | +1.7% | +0.9% | +13.0% | +13.0% | +13.1% | +7.8% | +9.5% |
| Depreciation | 9.76 | 6.97 | 6.83 | 8.55 | 8.81 | 8.23 | 7.67 |
| Interest | 2.90 | 0.55 | 0.43 | 0.58 | 0.67 | 0.78 | 0.98 |
| Profit before tax | 0.52 | 25.23 | 97.27 | 50.73 | 47.29 | 27.45 | 28.98 |
| Tax | 2.01 | 8.02 | 21.87 | 14.56 | 12.04 | 5.30 | 9.79 |
| Net profit | (1.72) | 16.86 | 75.40 | 36.16 | 32.88 | 21.40 | 18.97 |
| Net profit margin | -0.5% | +4.9% | +20.8% | +10.6% | +10.5% | +8.7% | +5.9% |
| EPS (₹) | (2.62) | 30.14 | 132.15 | 63.38 | 61.78 | 38.80 | 33.59 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 5.71 | 5.71 | 5.71 | 5.71 | 5.71 | 5.71 | 5.71 |
| Reserves & surplus | 386 | 387 | 377 | 306 | 274 | 239 | 217 |
| Shareholders' funds (net worth) | 392 | 392 | 383 | 312 | 279 | 244 | 223 |
| Secured loans | 28.48 | 10.05 | 2.10 | 3.97 | 3.77 | 0.43 | 1.44 |
| Unsecured loans | 1.10 | 2.27 | 1.22 | 1.35 | 1.90 | 1.19 | 0.60 |
| Total debt | 29.58 | 12.32 | 3.32 | 5.32 | 5.67 | 1.62 | 2.04 |
| Total liabilities | 428 | 412 | 398 | 329 | 298 | 261 | 240 |
| Assets | |||||||
| Gross block | 262 | 253 | 233 | 224 | 224 | 212 | 212 |
| Net block | 99.65 | 98.78 | 83.39 | 80.03 | 87.68 | 83.96 | 91.00 |
| Capital work in progress | 20.77 | 1.92 | 6.74 | 2.72 | 0.81 | 0.75 | 1.52 |
| Investments | 243 | 260 | 273 | 193 | 183 | 138 | 122 |
| Inventories | 58.27 | 63.90 | 43.61 | 50.68 | 39.18 | 35.75 | 42.72 |
| Sundry debtors | 33.92 | 27.37 | 29.33 | 30.33 | 25.07 | 19.49 | 30.13 |
| Cash & bank balances | 32.77 | 1.69 | 31.16 | 25.22 | 18.56 | 35.37 | 6.75 |
| Loans & advances | 24.39 | 18.86 | 13.23 | 31.23 | 14.50 | 18.54 | 23.69 |
| Total current assets | 149 | 112 | 117 | 137 | 97.31 | 109 | 103 |
| Total current liabilities | 86.20 | 93.19 | 96.32 | 94.24 | 104 | 79.36 | 80.38 |
| Net working capital | 63.15 | 18.63 | 21.01 | 43.22 | (7.09) | 29.79 | 22.91 |
| Total assets | 428 | 412 | 398 | 329 | 298 | 261 | 240 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.42 | 5.44 | 1.45 | 2.28 | 2.64 | 6.42 | 6.41 |
| Net cash from operating activities | (7.66) | (28.44) | 45.50 | 10.52 | 40.36 | 36.61 | 30.25 |
| Net cash from investing activities | (4.38) | 23.30 | (33.24) | (4.98) | (39.62) | (36.68) | (19.92) |
| Net cash from financing activities | 11.92 | 0.11 | (8.27) | (6.36) | (4.88) | (1.71) | (10.33) |
| Net change in cash | (0.12) | (5.02) | 3.99 | (0.83) | (4.13) | (1.77) | 0.00 |
| Closing cash | 32.77 | 1.69 | 31.16 | 25.22 | 18.56 | 35.37 | 6.75 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -3.5% | -4.6% | +6.1% | +9.0% | +26.7% | -22.9% | - |
| EBITDA growth | +80.8% | -93.3% | +5.7% | +8.6% | +112.3% | -36.8% | - |
| PBT growth | -97.9% | -74.1% | +91.7% | +7.3% | +72.3% | -5.3% | -23.3% |
| Net income growth | -110.2% | -77.6% | +108.5% | +10.0% | +53.6% | +12.8% | - |
| Revenue CAGR (3Y) | -0.8% | +3.3% | +13.6% | +2.1% | -0.4% | -4.9% | +2.8% |
| EBITDA CAGR (3Y) | -49.5% | -57.4% | +34.6% | +13.4% | +11.0% | +1.9% | +4.3% |
| Profitability & leverage | |||||||
| Net income margin | -0.5% | +5.0% | +20.8% | +10.6% | +11.2% | +9.0% | +6.0% |
| Return on capital employed | +0.8% | +6.4% | +26.9% | +16.4% | +17.2% | +11.3% | +12.9% |
| Return on net worth | -0.4% | +4.4% | +21.7% | +12.2% | +13.5% | +9.5% | +8.9% |
| Debt / equity | 0.05 | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | -71.96 | -14.47 | 1.07 | 1.62 | 2.09 | 7.06 | 4.29 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.30 | 1.42 | 1.59 | 1.53 | 1.44 | 1.17 | 1.59 |
| Inventory turnover | 5.46 | 6.43 | 7.69 | 7.60 | 8.37 | 6.31 | 7.39 |
| Debtors turnover | 10.89 | 12.20 | 12.15 | 12.35 | 14.07 | 9.97 | 12.36 |
| EPS (₹) | (2.62) | 30.14 | 132.15 | 63.38 | 61.78 | 38.80 | 33.59 |
| Dividend per share (₹) | 5.00 | 5.00 | 11.50 | 9.00 | 9.00 | 6.00 | 7.00 |
| Book value per share (₹) | 686.04 | 687.70 | 671.05 | 545.93 | 489.68 | 428.20 | 390.38 |
To see the full year-wise statements and ratios of Albert David Ltd, buy the company report.
Board of directors of Albert David Ltd
Albert David has 9 current directors and 19 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Arun Kumar Kothari Also directs: Gillanders Arbuthnot & Co Ltd, Bharat Fritz Werner Limited, Arunudaya Consultancy Private Limited and 4 more | Whole-Time Director | 20 Jun 1988 | 38 Years 4 Months | Current |
| Prabhawati Devi Kothari Also directs: Gillanders Arbuthnot & Co Ltd, Bharat Fritz Werner Limited, G Das & Co Pvt Ltd and 1 more | Director | 31 Mar 2014 | 12 Years 6 Months | Current |
| Monjori Mitra | Director | 24 Aug 2020 | 6 Years 1 Months | Current |
| Anand Vardhan Kothari Also directs: Bharat Fritz Werner Limited, Shubh Ananda Advisory Private Limited, Kothari Phytochemicals & Industries Ltd and 1 more | Director | 11 May 2022 | 4 Years 5 Months | Current |
| Rajiv Anant Desai | Director | 02 Aug 2025 | 1 Years 2 Months | Current |
| Naresh Pachisia Also directs: Century Plyboards (India) Ltd., SKP Securities Ltd., Orbit Regency Maintenance Company Private Limited and 5 more | Director | 14 Nov 2024 | 1 Years 11 Months | Current |
Peer comparison
Albert David Ltd is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Halewood Laboratories Private Limited | ₹430.29 Cr (FY 2025) | 20.0% | Ahmedabad, Gujarat, India | |||
| Milan Laboratories (India) Private Limited | ₹429.23 Cr (FY 2024) | 42.0% | Thane, Maharashtra, India | |||
| Escientia Advanced Sciences Private Limited | ₹423.15 Cr (FY 2024) | 114.0% | Shameerpet, Telangana, India | |||
| Recipharm Pharmaservices Private Limited | ₹421.11 Cr (FY 2025) | -3.0% | Mumbai, Maharashtra, India | |||
| Aspiro Pharma Limited | ₹418.29 Cr (FY 2025) | 147.0% | Markook, Telangana, India | |||
| Scott-Edil Advance Research Laboratories & Education Limited | ₹418.23 Cr (FY 2025) | 17.0% | Chandigarh, India | |||
| Visa Drugs & Pharmaceuticals Private Limited | ₹414.04 Cr (FY 2016) | 32.0% | Kolkata, West Bengal, India | |||
| Themis Medicare Limited | ₹410.18 Cr (FY 2025) | 6.0% | Vapi, Gujarat, India | |||
| Skymap Pharmaceuticals Private Limited | ₹409.08 Cr (FY 2025) | 2.0% | New Delhi, Delhi, India | |||
| Albert David Ltdthis company | ₹333.6 Cr (FY 2026) | -₹1.72 Cr | -0.5% | -3.5% | 1,344 | Kolkata, West Bengal, India |
To see the full peer comparison of Albert David Ltd, buy the company report.
Auditor
Albert David Ltd is audited by L. B. Jha & Co. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| L. B. Jha & Co. | FY 2023 | 301088E |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 62.20%, foreign institutional investors hold 0.60%, domestic institutional investors hold 1.60% and retail and other public shareholders hold 35.60%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 62.20% | 62.20% | 62.20% | 62.20% |
| Public | 37.80% | 37.80% | 37.80% | 37.80% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 06 May 2025 | 101089563 | Others | ₹20 Cr | Open | |
| 18 May 2004 | 80017415 | State Bank of India | ₹18.5 Cr | Open | |
| 17 Jun 1981 | 80016954 | State Bank of India | ₹17.5 Cr | Open | |
| 31 Aug 2015 | 10593412 | State Bank of India | ₹35 Cr | Satisfied | |
| 13 Jul 2009 | 10168910 | State Bank of India | ₹8 Cr | Satisfied |
To see the full charge records of Albert David Ltd, buy the company report.
Total charge records: 5 View all charges
Deals & funding
Albert David Ltd has 34 deals on record (33 market trades, 1 acquisition); the latest was in August 2024.
Deals on record (5 of 34)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Aug 2024 | Market trade | ₹4.8 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Aug 2024 | Market trade | ₹5.05 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Aug 2024 | Market trade | ₹8.7 Cr | Buyer: Graviton Research Capital LLP , Param Capital Seller: Graviton Research Capital LLP |
| Jan 2024 | Market trade | ₹6.68 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Jan 2022 | Market trade | ₹2.46 Cr | Buyer: XTX Markets LLP Seller: XTX Markets LLP |
To see the full deal history of Albert David Ltd, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Albert David Ltd has 177 court cases on record: 73 filed by Albert David, 104 filed against it. 36 cases are pending and 141 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 84 | 30 | 9 |
| District courts | 83 | 67 | 26 |
| Supreme Court | 10 | 7 | 1 |
Cases on record (5 of 177)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Supreme Court | Court case (3801-Matters Relating To Consumer Protection : Appeals u/s 23 of Consumer Protection Act, 1986.) | Filed against the company by National Insurance Co. Ltd. Through Manager Registered Office: 3, Middleton Street P.S. Park Street ,Kolkata , West Bengal | Disposed |
| High Court, West Bengal | Court case (IPDATM) | Filed against the company by Tosc International Pvt Ltd(Ora /293/13/Tm/Kol) Na | Disposed |
| District court, Central, Delhi | Civil suit | Filed by the company against Ms Macin Remedies Pvt. Ltd. | Disposed |
| Supreme Court | Court case | Filed against the company by The Commissioner of Customs (Port) Kolkata | Pending |
| District court, Central, Delhi | Court case (L I D) | Filed against the company by an individual | Pending |
To see the full case history of Albert David Ltd, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Albert David Ltd was last rated by Care on 06 Sep 2023.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 06 Sep 2023 |
To see the full credit ratings and regulatory alerts of Albert David Ltd, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Albert David Ltd; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Albert David Ltd has a workforce of 1,344 employees on its EPFO records as of Apr 07, 2024, across 4 active EPFO establishments.
GST
Albert David has 21 GST registrations: 8 active and 13 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 19AACCA3933D1ZZ | West Bengal | Active | 01 Jul 2017 |
| 19AACCA3933D2ZY | West Bengal | Active | 21 Sep 2017 |
| 05AACCA3933D1Z8 | Uttarakhand | Active | 01 Jul 2017 |
| 09AACCA3933D1Z0 | Uttar Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Albert David Ltd, buy the company report.
Recent activity
Albert David Ltd has 40 board changes on record since 1984: 25 appointments and 15 cessations. The latest: Amit Mahla was appointed as Additional Director on 19 Jun 2026.
41 earlier events are in the company report.
News
Frequently asked questions
Albert David is an active public limited company based in Kolkata, West Bengal, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 16 November 1938 (88+ years old) and is registered under CIN L51109WB1938PLC009490. Listed on BSE: 524075 and NSE: ALBERTDAVD.
Albert David reported revenue of ₹333.6 Cr for FY 2025-26 (down 3.5% YoY) based on standalone financials.
Albert David has 9 current directors:
- Arun Kumar Kothari - Whole-Time Director
- Prabhawati Devi Kothari - Director
- Monjori Mitra - Director
- Anand Vardhan Kothari - Director
- Rajiv Anant Desai - Director
- Naresh Pachisia - Director
- Anurag Singhi - Director
- Shourya Sengupta - Director
- Amit Mahla - Additional Director
The latest financial statements of Albert David on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 02 August 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Albert David is 19AACCA3933D1ZZ, registered in West Bengal. The company has 21 GST registrations in all, of which 8 are active and 13 are cancelled or inactive. Other active GSTINs include 19AACCA3933D2ZY (West Bengal), 05AACCA3933D1Z8 (Uttarakhand), 09AACCA3933D1Z0 (Uttar Pradesh).
The CIN (Corporate Identification Number) of Albert David is L51109WB1938PLC009490. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Albert David is a listed company as per MCA records. Its shares are listed on both BSE (code: 524075) and NSE (symbol: ALBERTDAVD).
Albert David has 177 court cases on record: 73 filed by the company and 104 filed against it. 36 are pending. Most are in the high courts.
Albert David was incorporated on 16 November 1938, making it 88+ years old. It is registered with the Registrar of Companies, Kolkata.
Albert David has 34 deals on record (33 market trades, 1 acquisition); the latest was in August 2024.
The peers of Albert David by revenue are Halewood Laboratories Private Limited, Milan Laboratories (India) Private Limited, Escientia Advanced Sciences Private Limited, Recipharm Pharmaservices Private Limited, Aspiro Pharma Limited and 4 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).